Mural Oncology plc (MURA)
USD 3.19
(-5.9%)
USD 3.19
(-5.9%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | - | - | - |
| Cost of Revenue | 2.56 Million | 1.54 Million | 1.47 Million |
| Gross Profit | -2.56 Million | -1.54 Million | -1.47 Million |
| Operating Expenses | 192.07 Million | 195.14 Million | 175.36 Million |
| Selling, General and Administrative Expenses | 30.03 Million | 25.07 Million | 15.54 Million |
| Research and Development Expenses | 162.03 Million | 170.06 Million | 159.81 Million |
| Other Expenses | - | - | - |
| Cost and Expenses | 194.63 Million | 195.14 Million | 175.36 Million |
| Operating Income | -194.63 Million | -195.14 Million | -175.36 Million |
| Interest Expense | - | - | - |
| Income Tax Expense | 12.16 Million | 4.88 Million | 68 Thousand |
| Earnings before Tax | -195.28 Million | -195.14 Million | -175.36 Million |
| Net Income | -207.44 Million | -200.03 Million | -175.43 Million |
| Earnings Per Share Basic | -12.43 | -11.99 | -10.51 |
| Earnings Per Share Diluted | -12.43 | -11.99 | -10.51 |
| Weighted Average Shares Outstanding | 16.68 Million | 16.68 Million | 16.68 Million |
| Weighted Average Shares Outstanding (Diluted) | 16.68 Million | 16.68 Million | 16.68 Million |
| Gross Margin | - | - | - |
| EBIT Margin | - | - | - |
| Profit Margin | - | - | - |
| EBITDA | -192.72 Million | -183.38 Million | -173.89 Million |
| Earnings Before Tax Margin | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 2.61 Million | - | - | - |
| Cost of Revenue | 900 Thousand | 846 Thousand | 613 Thousand | 2.56 Million | 779 Thousand | - |
| Gross Profit | -900 Thousand | -846 Thousand | 2 Million | -2.56 Million | -779 Thousand | - |
| Operating Expenses | 33.37 Million | 33.18 Million | 58.51 Million | 192.07 Million | 46.31 Million | 49.4 Million |
| Selling, General and Administrative Expenses | 6.23 Million | 6.61 Million | 16.27 Million | - | 5.95 Million | 6.7 Million |
| Research and Development Expenses | 27.14 Million | 26.56 Million | 42.24 Million | - | 40.35 Million | 42.7 Million |
| Other Expenses | 2.71 Million | 3.11 Million | - | - | - | - |
| Cost and Expenses | 34.27 Million | 34.03 Million | 58.51 Million | 194.63 Million | 46.31 Million | 49.4 Million |
| Operating Income | -34.27 Million | -34.03 Million | -58.51 Million | -194.63 Million | -46.31 Million | -49.4 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | 1.00 | 1.97 Million | 12.16 Million | 4.96 Million | 2.9 Million |
| Earnings before Tax | -31.56 Million | -30.91 Million | -57.56 Million | -195.28 Million | -46.31 Million | -49.4 Million |
| Net Income | -31.56 Million | -30.91 Million | -59.53 Million | -207.44 Million | -51.27 Million | -52.3 Million |
| Earnings Per Share Basic | -1.86 | -1.84 | -3.57 | - | -3.07 | -3.13 |
| Earnings Per Share Diluted | -1.86 | -1.84 | -3.57 | - | -3.07 | -3.13 |
| Weighted Average Shares Outstanding | 16.92 Million | 16.79 Million | 16.68 Million | 16.68 Million | 16.68 Million | 16.68 Million |
| Weighted Average Shares Outstanding (Diluted) | 16.92 Million | 16.79 Million | 16.68 Million | 16.68 Million | 16.68 Million | 16.68 Million |
| Gross Margin | - | - | 0.77 | - | - | - |
| EBIT Margin | - | - | -22.12 | - | - | - |
| Profit Margin | - | - | -22.74 | - | - | - |
| EBITDA | -33.37 Million | -33.18 Million | -57.89 Million | - | -45.53 Million | -48.75 Million |
| Earnings Before Tax Margin | - | - | -22.35 | - | - | - |
3470
3633
AMARIN
ZRFY
SGC
8064